Replies to post #1834 on Echo Therapeutics Inc fka ECTE

[bioresearcher]

Analyst price target $5.

"Lifetech Capital updated their research report on May 21st:

Our target price is based on 35x projected 2014 EPS and discounted 35% for risk resulting in a market capitalization of approximately $200 million. This is a significant discount to DexCom (DXCM) (see Competition), the only pure-play comparable, which has FDA approval for their invasive, implantable biosensors with a market capitalization of approximately $700 million."